RHY 15.6% $1.11 rhythm biosciences limited

Other research in this space, page-2

  1. 1,019 Posts.
    lightbulb Created with Sketch. 59
    Found this one too.First recuitment est 18/4/11 so not RHY related?

    Development of a better screening test for bowel cancer.
    Trial Information
    Trial summary

    This study aims to develop a more accurate screening test for colorectal cancer (CRC) by evaluating the accuracy of a panel of blood-based candidate biomarkers and to determine whether there is potential for recurrent cancers to be detected earlier with the new biomarker panel than the currently available blood tests. Who is it for? You may be eligible to join this study if you are aged 18 to 85 years old and are scheduled for colonoscopy for standard clinical indications.
    Participants with a diagnosis of colorectal cancer (CRC) who have been treated and are being monitored for recurrence will also be eligible for the second and third phase of the study.

    Study details: All participants in this study will be asked to undergo several tests for bowel cancer at the time of their routine hospital colonoscopy, the established gold standard bowel examination.
    The tests include, blood and saliva samples; and faecal occult blood tests which we will compare to new tests that we are developing that detect specific markers in blood. If we can reliably detect these markers then we will be able to develop a better screening test for bowel cancer.
    In patients who have been previously treated for bowel cancer and who are being monitored for signs of recurrence, we will also explore the use of the new biomarker blood test. It is hoped that this test may be more sensitive and detect recurrence much earlier than is now possible. The overall duration of observation in each participant is three years post surgery. For patients that undergo cancer resection prior to chemotherapy or radiotherapy, consent will be asked to obtain some tissue samples from any excess specimen from surgery (a cancer specimen and adjacent normal tissue). Tissue will have DNA extracted for analysis of biomarker levels to allow direct comparison to blood biomarker levels, as well as methylated BCAT1 and IKZF1 in the blood and surgical tissue. This will help to evaluate the accuracy and efficacy of the new blood-based screening test for bowel cancer.
    Broad Health Conditioncolorectal cancer.

    Specific Health ConditionCancer
    Bowel - Back passage (rectum) or large bowel (colon)

    Recruitment statusRecruiting

    Recruitment Details
    Recruitment State

    Flinders Medical Centre - Bedford Park

    Repatriation Hospital - Daw Park

    Noarlunga Health Service - Noarlunga Centre


    5168 - Noarlunga Centre

    Anticipated date of first participant enrolment18/04/2011

    Anticipated date of last participant enrolment30/06/2020

    Phase of Trial. ">Not Applicable

    Has the study received ethics approval?Approved

    Key inclusion criteria

    Patients scheduled for colonoscopy for standard clinical indications.
    Patients must be capable of providing satisfactory informed consent
    In addition for Phase 2b
    Cases with a diagnosis of CRC who have been treated and are being monitored for recurrence.
    Cases where tumour tissues and/or blood samples with associated consent for use in research are available

    Minimum age18 Years

    Maximum age85 Years

    GenderBoth males and females

    Can Healthy volunteers participate?No

    Key exclusion criteria

    Inability to provide informed consent
    Patients who undergo an incomplete colonoscopy which raises doubt as to the status of the colon (post-hoc exclusion).
    Contact details and further information
    SponsorPrimary Sponsor Type: Hospital
    Primary Sponsor Name: Flinders Medical Centre
    Primary Sponsor Address: 1 Flinders Drive Bedford Park 5042 South Australia
    Primary Sponsor Country: Australia

    Trial IDACTRN12611000318987

    Contact person for information and recruitmentMs
    Susie Byrne
    Department of Gastroenterology, Flinders Centre for Innovation in Cancer, Flinders Medical Centre, Bedford Park 5042
    +61 8 8204 7402
    +618 8204 6330
    [email protected]
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
(20min delay)
Mkt cap ! $224.4M
Open High Low Value Volume
98.0¢ $1.13 98.0¢ $1.194M 1.133M

Buyers (Bids)

No. Vol. Price($)
1 3656 $1.09

Sellers (Offers)

Price($) Vol. No.
$1.12 4000 2
View Market Depth
Last trade - 16.10pm 18/05/2021 (20 minute delay) ?
0.150 ( 14.6 %)
Open High Low Volume
98.0¢ $1.12 98.0¢ 48036
Last updated 15.54pm 18/05/2021 (live) ?
RHY (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.